Mineralys Therapeutics, Inc. - MLYS

SEC Filings Our MLYS Tweets

About Gravity Analytica

Recent News

08.04.2026 - Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026
07.27.2026 - Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
06.14.2026 - Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)
06.14.2026 - ENDO 2026: Lorundrostat Modulates Heart Failure Risk Biomarkers in Participants With Uncontrolled Hypertension
06.08.2026 - Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
06.08.2026 - Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)
06.03.2026 - Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
06.03.2026 - Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing
05.30.2026 - Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
05.27.2026 - Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference

Recent Filings